References
Baldwin DS (2008) Room for improvement in the pharmacological treatment of anxiety disorders. Curr Pharm Des 14:3482–3491
Baldwin DS, Ajel K (2007) The role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat 3:185–191
Baldwin DS, Anderson IM, Nutt DJ et al (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British association for psychopharmacology. J Psychopharmacol 19:567–596
Baldwin DS, Montgomery SA, Nil R et al (2007) Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 10:73–84
Baldwin DS, Schweitzer E, Lu Y, Lyndon G (2012) Does early improvement predict end-point response in patients with generalized anxiety disorder? Eur Neuropsychopharmacol 22:137–142
Baldwin DS, Stein DJ, Dolberg OT, Bandelow B (2009) How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum Psychopharmacol 24:269–275
Baldwin DS, Woods R, Lawson TD (2011) Efficacy of treatments for generalized anxiety disorder: systematic review and meta-analysis. BMJ 342:d1199
Bandelow B, Seidler-Brandler U, Becker A et al (2007) Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatr 8:175–187
Bandelow B, Zohar J, Hollander E et al (2008) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiatry 9:248–312
Chessick CA, Allen MH, Thase M et al (2006) Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev 3, CD006115
Hidalgo RB, Tupler LA, Davidson JRT (2007) An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 21:864–872
Pollack MH, Kornstein SG, Spann ME, Crits-Christoph P, Raskin J, Russell JM (2008) Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J Psychiatr Res 42:1176–1184
Rickels K, Shivitz TM, Ramey TS, Weaver JJ, Knapp LR, Miceli JJ (2012) Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychipharmacol 27:142–150
Stein MB, Schork NJ, Gelernter J (2008) Gene-by-environment (serotonin transporter and childhood maltreatment) interaction for anxiety sensitivity, an intermediate phenotype for anxiety disorders. Neuropsychopharmacology 33:312–319
Tyrer P, Baldwin DS (2006) Generalised anxiety disorder. Lancet 368:2156–2166
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Lader, M.S. (2013). Generalized Anxiety Disorder. In: Stolerman, I., Price, L. (eds) Encyclopedia of Psychopharmacology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27772-6_317-2
Download citation
DOI: https://doi.org/10.1007/978-3-642-27772-6_317-2
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Online ISBN: 978-3-642-27772-6
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences